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Cross-linking of radioiodinated interleukin-2 to murine CTLL-2 cells enabled etection of 70 kDa, 85 kDa and 105 kDa 
complexes of IL-2 and its binding proteins under the high-affinity binding condition. A series of anti-interleukin-2 mono- 
clonal antibodies (L15, L20, L23, L34, and L61) were tested for their activity to immunoprecipitate th se cross-linked 
complexes. L6 I, which had strong neutralizing activity, precipitated only the 70 kDa complex. L 15, L20, and L34, which 
also had neutralizing activity, precipitated not only the 70 kDa complex but also the 85 kDa complex. L23, which had 
practically no neutralizing activity, precipitated the 105 kDa complex as well as the 85 kDa complex. These results uggest 
that there are at least three distinct receptor binding sites for each receptor subunit on the interleukin-2 molecule, which 
are discernible by these monoclonal ntibodies and that the 105 kDa complex may play a significant role in the formation 
of the high-affinity receptor complex and the signal transduction. 
Monoclonal antibody; Interleukin-2; Interleukin-2 receptor; Crosslinking; Immunoprecipitation 
1. INTRODUCTION 
Interleukin-2 (IL-2) is a lymphokine produced by 
helper T cells, which induces proliferation and dif- 
ferentiation of both T [1] and B cells [2]. IL-2 ex- 
erts its effects through interaction with a specific 
receptor present on the surface membrane of 
responsive cells. There are at least two classes of 
IL-2 receptor (IL-2R) which differ in their af- 
finities for IL-2 [3]. Tac antigen (p55) was initially 
identified as the IL-2R using anti-Tac monoclonal 
antibody (mAb) [4]. However, cloning of the gene 
which encodes this protein revealed that, in con- 
trast to other known growth factor receptors, p55 
had a very short cytoplasmic tail which seemed in- 
sufficient for the possession of any enzymatic ac- 
tivity [5,6]. In addition, non-lymphoid cells 
transfected with p55 cDNA expressed only low- 
affinity IL-2R and failed to transduce the signal of 
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IL-2 [7]. Using radioiodinated IL-2 and chemical 
cross-linking methodology, a non-Tac IL-2 bind- 
ing protein of 70/75 kDa has been identified 
[8,9]. The p70/75 IL-2R expressed on LGL cells 
has an intermediate affinity for IL-2 in itself but is 
capable of transducing the signal of IL-2 [10]. It 
has been proposed that the p70/75 IL-2R 
associates with the p55 IL-2R to form the high- 
affinity IL-2R complex and has a domain responsi- 
ble for the signal transduction of IL-2. Recently, 
the murine IL-2R system has been found to possess 
a putative third subunit of 90-100 kDa associated 
with p55 and/or p70/75 [11,12]. However, despite 
the efforts of many laboratories, little is known at 
present about he function of p70/75 and p90/100. 
The same is true for the mechanism ofcomplex for- 
mation or interaction of IL-2 with these receptor 
subunits. 
Monoclonal antibodies have proven their use- 
fulness in studies on the relationship between the 
structure and function of ligands and their recep- 
tors. Murine hybridoma cell lines were previously 
established in our laboratory which produced 
mAbs (L15, L20, L23, L34, and L61) against 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/89/$3.50 © 1989 Federation of European Biochemical Societies 331 
Volume 250, number 2 FEBS LETTERS July 1989 
recombinant  human IL-2 (rlL-2) [13]. L61, which 
has strong neutralizing activity against IL-2 as 
determined by an inhibit ion experiment of CTLL-2 
cell growth, has strong inhibitory activity for IL-2 
binding to the high-affinity IL-2R as demonstrated 
by Scatchard analysis [14]. L15, L20, and L34 also 
inhibit  high-affinity binding of IL-2 and neutralize 
IL-2 activity. L23 inhibits only low-affinity binding 
of IL-2 and has practically no neutralizing activity 
[14]. In the present investigation, I used chemical 
cross-l inking methodology to analyze the high- 
aff inity IL-2R of murine CTLL-2 cells. SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE) 
analyses revealed the presence of p90 IL-2-binding 
protein as a component  of the high-affinity IL-2R. 
Immunoprecip i tat ion studies with the use of mAbs 
against r lL-2 offer evidence suggesting that p90 
plays a significant role in the signal transduct ion of
IL-2. 
2. MATERIALS  AND METHODS 
2.1. Cell culture condition 
IL-2-dependent murine CTLL-2 was kindly donated byPro- 
fessor Kumagai of Tohoku University. CTLL-2 was maintained 
in RPMI 1640 medium (Nissui & Co.) supplemented with 10% 
heat-inactivated fetal calf serum (Boehringer Mannheim), 2 mM 
L-glutamine, 1 mM sodium pyruvate, 50/zM 2-mercapto- 
ethanol, 100 U/ml penicillin G (Meiji), 100/~g/ml kanamycin 
(Meiji), 10 mM Hepes, pH 6.8, and 100 U/ml rlL-2. Cultures 
were maintained ina humidified incubator  37°C in an atmos- 
phere of 5°10 CO2 in air. 
2.2. mAbs 
The five anti-rlL-2 mAbs used, L15, L20, L23, L34, and 61
were previously characterized [13,14]. Subclass-matched con- 
trol mAbs were produced in my laboratory. All mAbs were 
purified from ascitic fluid by protein A-agarose affinity 
chromatography (Bio-Rad, MAPS II Kit). 
2.3. Chemical cross-linking 
[1251]IL-2 (Amersham) was chemically cross-linked to intact 
CTLL-2 cells as described by Tsudo et al. [9]. Briefly, CTLL-2 
cells (2 x 108) were incubated for 1 h at 4°C with 50 pM or 5 nM 
of [125I]IL-2 in a total volume of 3.2 ml ol¢culture medium (as 
described in section 2.1.) without rIL-2. After centrifugation 
(600×g, 5 min) through a 30-ml ayer of 1007o sucrose in 
phosphate-buffered saline (PBS), the cells were suspended in 4 
ml of PBS and cross-linked by adding 80/zl of 25 mM disuc- 
cirtimidyl suberate (Pierce) in dimethyl sulfoxide for 15 min at 
room temperature. To the reaction mixture was added 15 ml of 
10 mM Tris-HCl, pH 7.4, containing 1 mM EDTA and 0.14 M 
NaC1. After 5 min, cells were collected by centrifugation 
(600 x g, 5 min) and solubilized by incubating for 20 min at 4°C 
with 1.6 ml of PBS containing 1070 Triton X-100 and 1 mM 
phenylmethanesulfonyl fluoride (PMSF). 
2.4. Limited trypsin digestion of  IL-2R 
After cross-linking of [125I]IL-2, CTLL-2 cells were directly 
subjected to limited proteolysis by trypsin as described 
elsewhere [15]. Cross-linked cells (1.6 × l0s) were resuspended in 
150/zl of 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, and 0.14 M 
NaC1. L-1-Tosylamido-2-phenylethyl chloromethyl ketone- 
treated trypsin (2.5/zg, Worthington) was added in a volume of 
25/zl and the sample was incubated for 10 min to 2 h at 37°C. 
The reaction was terminated by adding 10-/A aliquots to 100/zl 
of PBS containing 1070 Triton X-100 and 1 mM PMSF. 
2.5. Immunoprecipitation 
Triton X-100 extracts of [125I]IL-2 cross-linked CTLL-2 cells 
were incubated with anti-IL-2 mAbs (final concentration was 
100 #g/ml) for 1 h at 4°C and precipitated with heat-killed 
formalin-fixed S. aureus Cowan I strain cells (SAC, Sigma) for 
1 h at 4°C. In some experiments, rabbit anti-mouse IgG 
subclass-specific antisera (Zymed) were used. The im- 
munoprecipitates were washed three times with MAPS II Kit 
binding buffer (Bio-Rad). 
2.6. SDS-PAGE 
SDS-PAGE was performed on cell extracts or immunopre- 
cipitates. The samples were mixed with half the volume of 
3 x concentrated SDS sample buffer (30 mM Tris-HC1, pH 6.8, 
20°70 glycerol, 307o SDS, and 0.0507o bromophenol blue) contain- 
ing 10070 2-mercaptoethanol and incubated in boiling water for 
5 min and subjected to SDS-PAGE using 7.5070 or 10070 
acrylamide gel according to Laemmli [16]. [lac]Methylated 
standard protein mixture (Amersham) was used as the molecular 
marker. The gels were dried and autoradiographed at -80°C 
for 3-21 days on Fuji HR-A film with a Fuji Grenex G-12 inten- 
sifying screen. 
3. RESULTS AND DISCUSSION 
To identify the murine IL-2-binding molecules, 
cross-l inking experiments were performed. SDS- 
PAGE (10070 acrylamide gel) of Tr i ton X-100 ex- 
tracts was carried out after chemically cross-linking 
CTLL-2 with [t25I]IL-2. Under the condit ion per- 
mitt ing the binding of IL-2 to only high-affinity 
sites (final concentrat ion of [125I]IL-2 was 50 pM) 
[3,8], radioactivity was detected in the bands cor- 
responding to a molecular mass of 65-70 kDa, 
80-85 kDa, 105 kDa, and 170-200 kDa (f ig. lA,  
lane b). In contrast, under the low-aff inity-binding 
condit ion (final concentrat ion of [125I]IL-2 was 5 
nM), only one band of 65-70 kDa was detected 
(fig. 1A, lane d). These bands were not detectable in
the presence of a 200-fold excess of unlabeled IL-2 
( f ig . lA,  lanes c and e), which indicates that 
[t25I]IL-2 bound cell membrane components at 
sites specific for IL-2. Since 70 kDa and 85-90 kDa 
complexes observed in human cell line studies have 
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Fig. 1. SDS-PAGE (10% acrylamide gel) of [t25I]IL-2 cross-linked to IL-2R. (A) Before cross-linking, CTLL-2 cells were incubated with 
50 pM (lanes b and c) or 5 nM (lanes d and e) [125I]IL-2 in the absence (lanes b and d) or presence (lanes c and e) of an excess amount 
of unlabeled IL-2. (B) Limited trypsin digestion of cross-linked IL-2R. After cross-linking, CTLL-2 cells were incubated with trypsin 
at 37°C for 0, 10, 20, 30, 40, 50, 60, 90, and 120 min (lanes b-j). 
been ascribed to complexes of a single 15 kDa IL-2 
molecule with p55 and p70/75 IL-2R subunit, 
respectively [8,9], it is very likely that the 65-70 
kDa and 80-85 kDa complexes observed in the 
murine cell system were also complexes between 
IL-2 with the p50/55 or the p65/70 IL-2R subunit. 
The 105 kDa complex has not been described for 
human cell lines, but was recently found in other 
mouse cell lines as a complex of IL-2 and p90 
IL-2R [11,12]. The bands of much higher mole- 
cular mass may be aggregates or complexes of 
receptor subunits as has been suggested for human 
[8] and mouse cell lines [11,12]. Since the human 
low-affinity IL-2R, p55 has been reported to be 
quantitatively cleaved into two fragments by tryp- 
sin [15], I tested mouse IL-2R subunits for their 
sensitivity to trypsin. [125I]IL-2 cross-linked p55 
IL-2R subunit was cleaved into 55 kDa and 30 kDa 
fragments by trypsin, but the higher molecular 
mass subunits p70 and p90 IL-2R were much more 
resistant o trypsin digestion than p55 (fig.lB, 
lanes b-j). These results rule out the possibility that 
p70 and p90 are homo- or hetero-dimers of p55. In- 
stead, they support he idea that p70 and p90 are 
distinct components of IL-2R. 
Anti-IL-2 mAbs, L15, L20, L34 and L61 recog- 
nized the high-affinity-binding sites of IL-2, while 
L23 recognized the low-affinity-binding site of 
IL-2 [14]. To determine which of the [125I]IL-2 
cross-linked IL-2R subunits is recognized by each 
mAb, I tested the ability of these mAbs to im- 
munoprecipitate th se [x25I]IL-2/IL-2R complexes. 
When SAC were used to recover the immune com- 
plex (fig.2, lanes a-e), L15, L20, and L34 pre- 
cipitated both the p55/IL-2 complex and the 
p70/IL-2 complex (fig.2, lanes a-c). L61 precipi- 
tated only the p55/IL-2 complex (fig. 2, lane d), 
whereas L23 precipitated only the p70/IL-2 com- 
plex (fig.2, lane e). Similar results were obtained 
when rabbit anti-immunoglobulin subclass-specific 
antisera (anti-IgGlfor L61, anti-IgG2b for other 
mAbs) were used to precipitate the immune com- 
plex. Here again, only p55/IL-2 complex was 
precipitated by L61 (fig.2, lane g) in contrast o 
L15 (fig.2, lane f; L20 and L34 also precipitated 
both p55/IL-2 and p70/IL-2 complexes). Inter- 
estingly, L23 could precipitate not only the 
p70/IL-2 complex but also the p90/IL-2 complex. 
A faint band of p55/IL-2 was also detectable 
(fig.2, lane h). Control IgG1 and IgG2b mAbs did 
not precipitate any complex (fig.2, lanes i and j). 
To analyze the higher molecular mass cross- 
linked protein, immunoprecipiates were run on the 
7.5o70 acrylamide gel SDS-PAGE (fig.3). The 135 
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Fig.2. SDS-PAGE (10070 acrylamide gel) of immunoprecipitates of cross-linked IL-2Rs by anti-IL-2 mAbs. After cross-linking, cell ex- 
tracts were immunoprecipitated with mAbs (L15, lanes a and f; L20, lane b; L34, lane c; L61, lanes d and g; L23, lanes e and h; control 
IgG~ mAb, lane i; control IgG2b mAb, lane j) using SAC (lanes a-e) or rabbit anti-mouse immunoglobulin subclass-specific antisera 
(lanes f-j). 
kDa complex was precipitated by L15, L20, and 
L34, but not by L61 or L23. Since L15, L20, and 
L34 were able to bind both p55/IL-2 and p70/IL-2, 
the most plausible explanation was that the 135 
Fig.3. SDS-PAGE (7.5070 acrylamide gel) of immunoprecipi- 
tates of cross-linked IL-2Rs by mAbs. After cross-linking, cell 
extracts were immunoprecipitated with mAbs (LI5, lane a; 20, 
lane b; L34, lane c; L61, lane d; L23, lane ;~control mAb, lane 
f) using rabbit anti-mouse immunoglobulin subclass-specific an-
tisera). 
kDa band was due to the ternary complex of p55, 
p70, and IL-2. the 125 kDa complex was precipi- 
tated by L61, and consisted presumably of IL-2 
and p55 homodimer. The reason that L15, L20, 
and L34 could not precipitate th 125 kDa complex 
is not clear at present, but it is possible that the 
homodimer formation conceals the binding sites 
for these mAbs. Further studies are needed to 
clarify these points. 
The results obtained from the immunoprecipita- 
tion experiments suggest he following models of 
action for these mAbs: L61 does not affect the bin- 
ding of IL-2 to p55 but inhibits the binding of IL-2 
to p70 and p90 ; L23 does not afect the binding of 
IL-2 to p70 and p90 but inhibits the binding of IL-2 
to p55; L15, L20, and L34 permit not only the bin- 
ding of IL-2to p55 and p70 but also the ternary 
complex formation between IL-2, p55 and p70. 
However these mAbs inhibit the binding of IL-2 to 
p90. 
These results on the activity pattern of anti-IL-2 
mAbs for binding the IL-2/ IL-2R complex, cou- 
• pied with our previous studies on the activity of 
these mAbs to inhibit both IL-2 binding to IL-2R 
and IL-2 dependent growth of CTLL-2 cells, reveal 
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the following mechanism of mAb-IL-2-2R interac- 
tion: L61, mAb with a strong neutralizing activity 
[13], binds IL-2 at its high-affinity-binding site 
[14], thereby preventing IL-2 from binding to p70 
and p90, while leaving the p55-binding site intact. 
The unavailability of IL-2 to p70 and/or p90 leads 
to cell growth inhibition. L23, which has practical- 
ly no neutralizing activity, binds IL-2 at its low- 
affinity-binding site [14], thereby preventing IL-2 
from binding to p55. Since p70 and p90 are accessi- 
ble to the IL-2-L23 complex, cells can grow in the 
presence of L23. L15, L20, and L34 bind IL-2 in 
such a way as to hinder its binding to p90. The 
resulting effect is the inhibition of high-affinity 
binding as revealed by Scatchard analyses [14]. p55 
and p70 are freely accessible to IL-2 in the presence 
of these mAbs, nevertheless, they inhibit IL-2- 
dependent cell growth [13]. 
These results suggest that CTLL-2 cell growth is 
dependent upon the accessibility of IL-2 to p90 
rather than p70. The p90/100 was recently reported 
as a possible high-affinity component in the murine 
IL-2R system [11,12]. The present results are con- 
sistent with these findings and offer further evi- 
dence for the possible role of p90 in signal trans- 
duction of IL-2 in the murine system. Recent ex- 
periments revealed that IL-2-induced phosphoryla- 
tion occurred at 85-100 kDa protein [17]. It is 
tempting to speculate that p90 is a preferential 
cellular substrate for receptor-associated kinase in- 
volved in cell growth and proliferation. 
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